A retrospective study evaluating the fracture risk among patients with atrial fibrillation (AF) treated with non-vitamin K antagonist oral anticoagulants (NOACs) or warfarin
Latest Information Update: 04 Feb 2020
At a glance
- Drugs Apixaban (Primary) ; Dabigatran etexilate (Primary) ; Rivaroxaban (Primary) ; Warfarin (Primary)
- Indications Thrombosis
- Focus Adverse reactions
Most Recent Events
- 04 Feb 2020 New trial record
- 01 Feb 2020 Results published in the European Heart Journal